Literature DB >> 18706450

Laboratory tests for evaluating the level of attenuation of bluetongue virus.

P Franchi1, M T Mercante, G F Ronchi, G Armillotta, S Ulisse, U Molini, M Di Ventura, R Lelli, G Savini, A Pini.   

Abstract

One of the most important steps when preparing a live attenuated vaccine is the assessment of the level of attenuation in target animals. It is costly and time consuming as it requires, on each occasion, a large number of susceptible animals and contained accommodation. This study assessed the consistency of the bovine foetal aorta endothelial (BFA) cell line and newborn mice for evaluating the attenuation level of BTV4, BTV9 and BTV16 Italian field isolates. Following serial passages in BHK(21c13) or Vero cell cultures, BTV attenuated clones demonstrated a reduced replication capability in the BFA cells compared to the homologous virulent strains. Similarly, following intracerebral inoculation, the attenuated clones were completely innocuous to newborn mice contrary to the homologous virulent strains which killed all animals within 10 days. Vaccines produced with the BTV9 or BTV4 attenuated clones were safe, immunogenic and capable of preventing clinical symptoms and viraemia in sheep following challenge with homologous virulent virus. The two assays may be valuable indicators of the gradual changes occurring in the BTV population leading to virus attenuation, they can predict the safety of a BTV attenuated vaccine and, in turn, reduce the number of sheep and cattle required to assess the level of attenuation attained.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706450     DOI: 10.1016/j.jviromet.2008.07.007

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Determinants of bluetongue virus virulence in murine models of disease.

Authors:  Marco Caporale; Rachael Wash; Attilio Pini; Giovanni Savini; Paola Franchi; Matthew Golder; Janet Patterson-Kane; Peter Mertens; Luigina Di Gialleonardo; Gisella Armillotta; Rossella Lelli; Paul Kellam; Massimo Palmarini
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 2.  Strategies for Assessing Arbovirus Genetic Variability in Vectors and/or Mammals.

Authors:  Camille Victoire Migné; Sara Moutailler; Houssam Attoui
Journal:  Pathogens       Date:  2020-11-05

3.  Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor.

Authors:  Eva Calvo-Pinilla; Teresa Rodríguez-Calvo; Juan Anguita; Noemí Sevilla; Javier Ortego
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

4.  Identification and characterization of a novel non-structural protein of bluetongue virus.

Authors:  Maxime Ratinier; Marco Caporale; Matthew Golder; Giulia Franzoni; Kathryn Allan; Sandro Filipe Nunes; Alessia Armezzani; Amr Bayoumy; Frazer Rixon; Andrew Shaw; Massimo Palmarini
Journal:  PLoS Pathog       Date:  2011-12-29       Impact factor: 6.823

5.  Duration of protective immunity after a single vaccination with a live attenuated bivalent bluetongue vaccine.

Authors:  Kuandyk Zhugunissov; Zakir Yershebulov; Kainar Barakbayev; Yerbol Bulatov; Dmitriy Taranov; Zhanat Amanova; Yergali Abduraimov
Journal:  Vet Res Commun       Date:  2015-08-18       Impact factor: 2.459

6.  Characterization of a second open reading frame in genome segment 10 of bluetongue virus.

Authors:  Meredith Stewart; Alexandra Hardy; Gerald Barry; Rute Maria Pinto; Marco Caporale; Eleonora Melzi; Joseph Hughes; Aislynn Taggart; Anna Janowicz; Mariana Varela; Maxime Ratinier; Massimo Palmarini
Journal:  J Gen Virol       Date:  2015-08-19       Impact factor: 3.891

Review 7.  A review of experimental infections with bluetongue virus in the mammalian host.

Authors:  Peter Coetzee; Moritz van Vuuren; Estelle H Venter; Maria Stokstad
Journal:  Virus Res       Date:  2014-01-24       Impact factor: 3.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.